2025年，药企营收TOP10名单中，大部分公司实现了业绩增长。礼来凭借GLP-1药物的爆发式增长，营收飙升45%，排名大幅跃升，跻身全球制药企业营收前三。另一家排名上升的赛诺菲则手握度普利尤单抗这一自免重磅炸弹，推动公司营收在2025年增长了10%，达到436亿欧元。然而，辉瑞和BMS两家公司在增长动能转换的挑战下，营收出现下滑。而在2024年TOP10药企均实现了业绩增长。表1 2025年全球...
Source Link2025年，药企营收TOP10名单中，大部分公司实现了业绩增长。礼来凭借GLP-1药物的爆发式增长，营收飙升45%，排名大幅跃升，跻身全球制药企业营收前三。另一家排名上升的赛诺菲则手握度普利尤单抗这一自免重磅炸弹，推动公司营收在2025年增长了10%，达到436亿欧元。然而，辉瑞和BMS两家公司在增长动能转换的挑战下，营收出现下滑。而在2024年TOP10药企均实现了业绩增长。表1 2025年全球...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.